Suppr超能文献

胰腺功能不全时口服酶的命运:两种胰酶制剂的比较。

Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two pancreatic enzyme preparations.

作者信息

Delchier J C, Vidon N, Saint-Marc Girardin M F, Soule J C, Moulin C, Huchet B, Zylberberg P

机构信息

Department of Gastroenterology, Hôpital Henri Mondor, Créteil, France.

出版信息

Aliment Pharmacol Ther. 1991 Aug;5(4):365-78. doi: 10.1111/j.1365-2036.1991.tb00040.x.

Abstract

The effect on steatorrhoea of a pH-sensitive enteric-coated pancreatic preparation (Eurobiol 25,000) was compared with a conventional pancreatic enzyme preparation (Eurobiol) in six adult patients with exocrine pancreatic insufficiency. In addition, the fate of orally ingested pancreatic enzymes in the upper digestive tract was evaluated by measuring gastric and duodenal pH, amount of enzymes in the stomach, duodenal enzyme output, and fat absorption at the angle of Treitz for the 4 hours following a standard meal. When compared with placebo, Eurobiol and Eurobiol 25,000 reduced daily faecal fat excretion by 24% (not significant) and 43% (P less than 0.05), respectively. With the conventional preparation, enzyme output and fat absorption at the duodeno-jejunal flexure were significantly improved (P less than 0.05). Marked inter-individual differences in duodenal enzyme recovery (lipase 3% to 80%; chymotrypsin 26% to 100%) and, consequently, in the reduction of steatorrhoea (0% to 67%) were observed, with the gastric emptying rate emerging as a key determinant factor. With the enteric-coated preparation, enzyme output and fat absorption at the duodenojejunal flexure were not significantly improved. Discrepancy between the marked reduction of faecal fat excretion and the low duodenal enzyme recovery could indicate that enzyme delivery from microtablets occurs further down in the small bowel. Efficacy of enteric-coated preparations could be enhanced by adding unprotected enzymes, especially in patients with rapid gastric emptying.

摘要

在6名患有外分泌性胰腺功能不全的成年患者中,将一种pH敏感型肠溶包衣胰腺制剂(欧洲生物制剂25,000)对脂肪泻的影响与一种传统胰腺酶制剂(欧洲生物制剂)进行了比较。此外,通过测量标准餐后4小时的胃和十二指肠pH值、胃内酶量、十二指肠酶输出量以及Treitz角处的脂肪吸收情况,评估了口服胰腺酶在上消化道中的命运。与安慰剂相比,欧洲生物制剂和欧洲生物制剂25,000分别使每日粪便脂肪排泄量减少了24%(无显著差异)和43%(P<0.05)。使用传统制剂时,十二指肠-空肠弯曲处的酶输出量和脂肪吸收量有显著改善(P<0.05)。观察到十二指肠酶回收率存在明显的个体差异(脂肪酶为3%至80%;糜蛋白酶为26%至100%),因此脂肪泻的减少程度也存在差异(0%至67%),胃排空率是一个关键决定因素。使用肠溶包衣制剂时,十二指肠-空肠弯曲处的酶输出量和脂肪吸收量没有显著改善。粪便脂肪排泄量显著减少与十二指肠酶回收率较低之间的差异可能表明,微片释放的酶在小肠更下游的部位发挥作用。添加未受保护的酶可以提高肠溶包衣制剂的疗效,尤其是在胃排空迅速的患者中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验